Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Relapsed/Refractory AML with NPM1 Mutation
NCT01835288Phase 2Withdrawn
- Sponsor
- Stanford University
- Start
- May 2013
- Primary completion
- May 2015
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in acute myeloid leukemia (AML), sponsored by Stanford University. Primary endpoint: Rate of complete remission following arsenic trioxide induction at 4 weeks. Planned start May 2013; status: withdrawn.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01835288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01835288.